Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 48.67%.

  • Apellis Pharmaceuticals' EBIT Margin rose 726900.0% to 48.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.91%, marking a year-over-year increase of 391400.0%. This contributed to the annual value of 21.11% for FY2024, which is 1092800.0% up from last year.
  • Apellis Pharmaceuticals' EBIT Margin amounted to 48.67% in Q3 2025, which was up 726900.0% from 18.65% recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' EBIT Margin peaked at 48.67% during Q3 2025, and registered a low of 31185.71% during Q2 2021.
  • Moreover, its 5-year median value for EBIT Margin was 125.49% (2023), whereas its average is 2090.58%.
  • The largest annual percentage gain for Apellis Pharmaceuticals' EBIT Margin in the last 5 years was 302751400bps (2022), contrasted with its biggest fall of -5755900bps (2022).
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' EBIT Margin stood at 148.29% in 2021, then tumbled by -388bps to 723.88% in 2022, then skyrocketed by 92bps to 57.74% in 2023, then soared by 79bps to 12.31% in 2024, then surged by 495bps to 48.67% in 2025.
  • Its EBIT Margin was 48.67% in Q3 2025, compared to 18.65% in Q2 2025 and 49.96% in Q1 2025.